183 related articles for article (PubMed ID: 38181441)
21. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
Pérez-Herrero E; Fernández-Medarde A
Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
[TBL] [Abstract][Full Text] [Related]
22. Recent advances in siRNA delivery for cancer therapy using smart nanocarriers.
Zhang P; An K; Duan X; Xu H; Li F; Xu F
Drug Discov Today; 2018 Apr; 23(4):900-911. PubMed ID: 29373841
[TBL] [Abstract][Full Text] [Related]
23. Redox-responsive mesoporous silica nanoparticles: a physiologically sensitive codelivery vehicle for siRNA and doxorubicin.
Ma X; Teh C; Zhang Q; Borah P; Choong C; Korzh V; Zhao Y
Antioxid Redox Signal; 2014 Aug; 21(5):707-22. PubMed ID: 23931896
[TBL] [Abstract][Full Text] [Related]
24. Tumor-targeting multifunctional nanoparticles for siRNA delivery: recent advances in cancer therapy.
Ku SH; Kim K; Choi K; Kim SH; Kwon IC
Adv Healthc Mater; 2014 Aug; 3(8):1182-93. PubMed ID: 24577795
[TBL] [Abstract][Full Text] [Related]
25. Recent Advancements in the Design of Nanodelivery Systems of siRNA for Cancer Therapy.
Yadav DN; Ali MS; Thanekar AM; Pogu SV; Rengan AK
Mol Pharm; 2022 Dec; 19(12):4506-4526. PubMed ID: 36409653
[TBL] [Abstract][Full Text] [Related]
26. Cell penetrating peptides: efficient vectors for delivery of nanoparticles, nanocarriers, therapeutic and diagnostic molecules.
Farkhani SM; Valizadeh A; Karami H; Mohammadi S; Sohrabi N; Badrzadeh F
Peptides; 2014 Jul; 57():78-94. PubMed ID: 24795041
[TBL] [Abstract][Full Text] [Related]
27. Current Transport Systems and Clinical Applications for Small Interfering RNA (siRNA) Drugs.
Liu F; Wang C; Gao Y; Li X; Tian F; Zhang Y; Fu M; Li P; Wang Y; Wang F
Mol Diagn Ther; 2018 Oct; 22(5):551-569. PubMed ID: 29926308
[TBL] [Abstract][Full Text] [Related]
28. Oral delivery of shRNA and siRNA via multifunctional polymeric nanoparticles for synergistic cancer therapy.
Han L; Tang C; Yin C
Biomaterials; 2014 May; 35(15):4589-600. PubMed ID: 24613049
[TBL] [Abstract][Full Text] [Related]
29. Organ-restricted delivery through stimuli-responsive nanocarriers for lung cancer therapy.
Dinakar YH; Karole A; Parvez S; Jain V; Mudavath SL
Life Sci; 2022 Dec; 310():121133. PubMed ID: 36306866
[TBL] [Abstract][Full Text] [Related]
30. Lipid-based nanoparticles for siRNA delivery in cancer therapy: paradigms and challenges.
Gomes-da-Silva LC; Fonseca NA; Moura V; Pedroso de Lima MC; Simões S; Moreira JN
Acc Chem Res; 2012 Jul; 45(7):1163-71. PubMed ID: 22568781
[TBL] [Abstract][Full Text] [Related]
31. Smart Polymeric Nanoparticles with pH-Responsive and PEG-Detachable Properties (II): Co-Delivery of Paclitaxel and VEGF siRNA for Synergistic Breast Cancer Therapy in Mice.
Jin M; Hou Y; Quan X; Chen L; Gao Z; Huang W
Int J Nanomedicine; 2021; 16():5479-5494. PubMed ID: 34413645
[TBL] [Abstract][Full Text] [Related]
32. In Situ Synthesis of Ultrathin ZIF-8 Film-Coated MSNs for Codelivering Bcl 2 siRNA and Doxorubicin to Enhance Chemotherapeutic Efficacy in Drug-Resistant Cancer Cells.
Pan QS; Chen TT; Nie CP; Yi JT; Liu C; Hu YL; Chu X
ACS Appl Mater Interfaces; 2018 Oct; 10(39):33070-33077. PubMed ID: 30203954
[TBL] [Abstract][Full Text] [Related]
33. A theranostic micelleplex co-delivering SN-38 and VEGF siRNA for colorectal cancer therapy.
Lee SY; Yang CY; Peng CL; Wei MF; Chen KC; Yao CJ; Shieh MJ
Biomaterials; 2016 Apr; 86():92-105. PubMed ID: 26896610
[TBL] [Abstract][Full Text] [Related]
34. Nanoparticulate RNA delivery systems in cancer.
Sharma A; Jha NK; Dahiya K; Singh VK; Chaurasiya K; Jha AN; Jha SK; Mishra PC; Dholpuria S; Astya R; Nand P; Kumar A; Ruokolainen J; Kesari KK
Cancer Rep (Hoboken); 2020 Oct; 3(5):e1271. PubMed ID: 32729987
[TBL] [Abstract][Full Text] [Related]
35. Nanocarrier Mediated siRNA Delivery Targeting Stem Cell Differentiation.
Fernandes F; Kotharkar P; Chakravorty A; Kowshik M; Talukdar I
Curr Stem Cell Res Ther; 2020; 15(2):155-172. PubMed ID: 31789134
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of osteoclastogenesis through siRNA delivery with tunable mesoporous bioactive nanocarriers.
Kim TH; Singh RK; Kang MS; Kim JH; Kim HW
Acta Biomater; 2016 Jan; 29():352-364. PubMed ID: 26432439
[TBL] [Abstract][Full Text] [Related]
37. Polymers in the Co-delivery of siRNA and Anticancer Drugs for the Treatment of Drug-resistant Cancers.
Sun H; Yarovoy I; Capeling M; Cheng C
Top Curr Chem (Cham); 2017 Apr; 375(2):24. PubMed ID: 28176270
[TBL] [Abstract][Full Text] [Related]
38. Design of doxorubicin encapsulated pH-/thermo-responsive and cationic shell-crosslinked magnetic drug delivery system.
Mdlovu NV; Lin KS; Weng MT; Lin YS
Colloids Surf B Biointerfaces; 2022 Jan; 209(Pt 2):112168. PubMed ID: 34715504
[TBL] [Abstract][Full Text] [Related]
39. Hybrid protein-inorganic nanoparticles: From tumor-targeted drug delivery to cancer imaging.
Elzoghby AO; Hemasa AL; Freag MS
J Control Release; 2016 Dec; 243():303-322. PubMed ID: 27794493
[TBL] [Abstract][Full Text] [Related]
40. Polymeric nanocarriers for siRNA delivery to murine macrophages.
Forbes DC; Peppas NA
Macromol Biosci; 2014 Aug; 14(8):1096-105. PubMed ID: 24753265
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
